Redeye comments on SciBase’s rights issue. The announcement came as no surprise, as we had already incorporated an equity raise into our mod...
Redeye provides an update following SciBase’s Q2 2026 report.
Redeye provides an initial take following SciBase’s Q2 2026 report.
Redeye comments on the announcement that Pia Renaudin has decided to step down as CEO of SciBase.
SciBase announced this morning that it has submitted a 510(k) premarket notification to the FDA seeking to expand the indication for Nevisen...
Redeye returns with an update following SciBase Holding’s Q1 report, which largely met our expectations.
SciBase’s Q1 report aligned closely with our projections.
Redeye returns with an update following SciBase Holding’s Q4 report.
Redeye provides an initial comment on SciBase's Q4 report, where sales came in somewhat above our estimates, while costs were higher than ex...
Redeye comments on SciBase announcing a newly published study evaluating the use of Nevisense for assessing skin barrier impairment.
Redeye positively views the FDA approval of extended labelling for Nevisense, allowing measurements to be performed by additional healthcare...
Redeye positively views the inclusion of Nevisense (EIS) in the US National Comprehensive Cancer Network (NCCN) melanoma guidelines in the c...
Redeye comments on the new Nevisense data in atopic dermatitis (AD).
Scibase has now disclosed the final outcome of its rights issue, in addition to announcing the outcome of the repurchase of outstanding warr...
Redeye provides an update following Scibase’s Q3 report and intensive news flow last Friday.
Redeye provides a brief comment on Scibase receiving an initial order valued at approximately SEK8m from Castle Biosciences.
Yesterday, Scibase announced that Ribbskottet AB and Life Science Investment Fund (LSIF), have each bought around 7.
Redeye returns with a more in-depth take on Q2 earnings.
Redeye provides an initial comment on Scibase’s Q2 report, which came in slightly below our estimates.
Redeye comments on Scibase entering a collaboration and license agreement with Castle Biosciences and conducting a directed share issue of S...
Redeye provides a brief comment on today’s news regarding Scibase's first order in Italy.
Redeye returns with a more in-depth take on the Q1 earnings.
Scibase is steadily executing on its long-term strategy, with the US and Germany continuing to drive growth.
Redeye has interviewed Pia Renaudin, CEO at Scibase, in connection with the Q1 report.
Redeye saw a Q4 report in which sales exceeded our estimates.
Redeye saw a Q4 report showing sales above our estimates, with a total growth of 49% for the quarter.
Redeye comments on further news from the all-important US market.
Redeye comments on SciBase’s announcement of its preliminary results for the capital raise this morning.
Redeye comments on announcing a new pilot involving the renowned Mayo Clinic.
Redeye saw a Q3 report in which sales and gross margins slightly exceeded our estimates.
Redeye saw a Q3 report showing sales above our estimates, with a total growth of 16% for the quarter.
Redeye comments on the steps to introduce Scibase solutions to other countries further.
Redeye comments on the announcement of sales of the Nevisense device to NIH as a research tool on the microbiome and interactions with atopi...
Redeye comments on the steps in the US to expand the footprint.
Redeye is favorable to the further validation of Nevisense in the US.
Redeye saw a Q2 report in which sales and gross margins did not deviate much from our expectations, while costs due to the increased pace in...
Redeye saw a Q2 report showing sales slightly below our estimates, with a total growth of 31% for the quarter.
Redeye comments on the continued expansion into California with a new collaboration with United Health with nine clinics.
Redeye saw a mixed Q1 report, as sales and gross margins did not deviate much from our expectations, while costs increased faster than antic...
Redeye saw a Q1 report showing sales slightly below our estimates, with a total growth of 18% for the quarter.
Redeye comments on the launch of the new eBarrier score, an AI skin barrier assessment tool for research and cosmetic testing.
Redeye notes that a new German clinical study has been published, presenting the improvement the Nevisense provided over visual and dermosco...
Redeye comments on the outcome of the first step of the capital raise.
Redeye comments on today’s news. Scibase has resolved a directed issue of c SEK 33m and a rights issue of c SEK 15m or a total of SEK 48m be...
Redeye comments on Scibase’s new partnership within the Barrier field.
Redeye saw a Q4 report showing sales below our estimates, with a total growth of 16% for the quarter.
Redeye comments on the business update by CEO Pia Renaudin after the initial 100 days at Scibase.
Redeye views favorably the news that Scibase has entered into a collaboration with the Skin and Cancer Institute for a pilot test in some cl...
Redeye saw a Q3 report that was both better and weaker than expected.
Redeye saw a Q3 report showing sales above our estimates, with a total growth of 47% for the quarter.
Redeye comments on the second published study in two days regarding the Skin Barrier field from Scibase.
Redeye is encouraged by the publication of the clinical results from a study at the University Children’s Hospital in Zürich.
Redeye is favorable to the initiation of a new pilot with Bare Dermatology based in Texas.
Redeye is positive that Scibase has hired Dan Walker to become VP of US commercial operations.
Redeye’s short comment on the new CEO appointment.
Redeye saw a Q2 report that was slightly weaker on the top line, with higher costs, making for a lower outcome than expected.
Redeye saw a Q2 report showing sales slightly below our estimates in real terms, with a total growth of 36% for the quarter.
Redeye comments on the recent progress update from Scibase and our research into fee schedules for selected MACs in the US.
Redeye’s short comment on the announced management change.
Redeye saw a Q1 report that was slightly weaker than expected but not a material deviation.
Redeye saw a Q1 report showing sales slightly below our estimates in real terms, while costs were generally in line.
Redeye views positively the news that two Medicare Administrative Contractors (MACs) have updated their fee schedules for Scibase’s early de...
Redeye updates the fair value range after the Q4 report and the share issue.
Redeye saw a Q4 report showing sales roughly in line with estimates, while costs were slightly higher, giving an EBIT result at SEK -13.
Redeye continues to see a very compelling ling term investment case.
Redeye is encouraged by the news that Scibase has entered into a collaboration with Johnson & Johnson to detect skin barrier and predict ato...
Redeye is positive as regards the results from a new study, further showing statistically significant improvement regarding correct biopsies...
Redeye updates our expectations on melanoma and NMSC and includes Barrier detection to our estimates for SciBase as we now see a real long-t...
Redeye views with interest the news regarding the Nevisense and EIS to assess the effect of commercial laundry detergents on the skin barrie...
